| Segment Reporting |
The following table contains additional information on our consolidated revenue and net loss, including significant segment expenses: | | | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended September 30, | | Nine Months Ended September 30, | | | | (In thousands) | 2026 | | 2025 | | 2026 | | 2025 | | | | Product revenue, net - U.S. | $ | 48,738 | | | $ | 12,320 | | | $ | 108,506 | | | $ | 33,197 | | | | | Product revenue, net - Rest of world | 6,647 | | | 560 | | | 12,370 | | | 864 | | | | | PK activator (PYRUKYND®/AQVESME®) direct expenses - research and development | (21,733) | | | (30,533) | | | (71,487) | | | (81,663) | | | | | Compensation and related expenses - research and development | (28,661) | | | (30,299) | | | (95,802) | | | (90,883) | | | | | Total selling, general and administrative expenses | (56,533) | | | (41,274) | | | (156,384) | | | (128,670) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Other segment items* | (13,503) | | | (14,207) | | | (62,062) | | | (37,587) | | | | | Net loss | $ | (65,045) | | | $ | (103,433) | | | $ | (264,859) | | | $ | (304,742) | | | |
*Other segment items primarily include cost of sales, other research and development expenses, and interest income.
|